Hyperbaric oxygen (HBO2) treatment for tissue damage
Hyperbaric oxygen treatment (HBOT) involves the systemic administration of pure gaseous oxygen under pressures greater than 1 atmosphere in a specialized chamber. Hyperbaric oxygen may also be administered in a multiplace chamber in which patients breathe 100% oxygen through a facemask or similar device with the surrounding air pressure increased to 2 to 3 times the atmospheric pressure.
Status: Review in progress
Why is HBOT being reviewed?
For HBO2 treatment (including wound care and treatment of Central Nervous Systems (CNS) conditions), important questions center on the effectiveness of treatment for some conditions, as well as the frequency, dose and duration treatment. The list of applications for HBO2 treatment has expanded beyond those approved by the Food and Drug Administration (FDA) or currently covered by the Center for Medicare Services (CMS).
Primary criteria ranking
- Safety = Medium
- Efficacy = High
- Cost = High
Documentation
| Type | Materials |
|---|---|
| Assessment (2025) | |
| Assessment (2013) |
Assessment timeline
- Draft key questions published: August 29, 2024
- Public comment period: August 29 to September 12, 2024
- Final key questions: September 26, 2024
- Draft report published: January 7, 2025
- Public comment period: January 7 to February 5, 2025
- Final report published: February 21, 2025
- HTCC public meeting: March 21, 2025
- Draft findings and decision published: March 31, 2025
- Public comment period: March 31 to April 14, 2025
- Final findings and decision published: Mary 22, 2025
All future dates are estimates and subject to change.